Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

NCT03610971 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Chronic Phase Chronic Myeloid Leukemia
Chronic Myeloid Leukemia, Chronic Phase

Interventions

DRUG: Ruxolitinib
DRUG: BCR-ABL Tyrosine Kinase Inhibitor (TKI)

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]
[object Object]